keyword
MENU ▼
Read by QxMD icon Read
search

HBsAg Clearance

keyword
https://www.readbyqxmd.com/read/28325923/clinical-features-and-viral-quasispecies-characteristics-associated-with-infection-by-the-hepatitis-b-virus-g145r-immune-escape-mutant
#1
Yuan Xue, Ming-Jie Wang, Zhi-Tao Yang, De-Min Yu, Yue Han, Dao Huang, Dong-Hua Zhang, Xin-Xin Zhang
Coexistence of the hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) is an uncommon phenomenon, and the underlying mechanisms remain largely unknown. Amino-acid (aa) substitution from glycine to arginine at aa 145 (G145R), in the major hydrophilic region, has been reported in patients with HBsAg and anti-HBs coexistence. However, there is limited knowledge about the clinical features and viral quasispecies characteristics associated with G145R mutant hepatitis B virus (HBV) infection...
March 22, 2017: Emerging Microbes & Infections
https://www.readbyqxmd.com/read/28321112/different-mechanisms-may-exist-for-hbsag-synthesis-and-secretion-during-various-phases-of-chronic-hepatitis-b-virus-infection
#2
Yunsong Li, Qun Cai, Qinxiu Xie, Yafei Zhang, Xiangling Meng, Zhenhua Zhang
BACKGROUND The aim of this study was to characterize the expression and secretion of hepatitis B surface-antigen (HBsAg) in the hepatocytes of hepatitis B virus (HBV)-infected patients at different phases of infection; as such, the association of intrahepatic HBsAg expression with virological markers and the histological characteristics were analyzed. MATERIAL AND METHODS 302 chronic HBV infection patients who had not received antiviral therapy were stratified by HBeAg status. The proportion of HBsAg-positive cells was used as an indicator for HBsAg expression level...
March 21, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28317872/preclinical-evaluation-of-the-efficacy-pharmacokinetics-and-immunogenicity-of-js-001-a-programmed-cell-death-protein-1-pd-1-monoclonal-antibody
#3
Jie Fu, Fang Wang, Li-Hou Dong, Jing Zhang, Cheng-Lian Deng, Xue-Li Wang, Xin-Yao Xie, Jing Zhang, Ruo-Xian Deng, Li-Bo Zhang, Hai Wu, Hui Feng, Bo Chen, Hai-Feng Song
JS-001 is the first monoclonal antibody (mAb) against programmed cell death protein-1 (PD-1) approved by the China Food and Drug Administration (CFDA) into the clinical trails. To date, however, no pre-clinical pharmacological and pharmacokinetic (PK) data are available. In this study, we investigated the efficacy of JS-001 and conducted a preclinical PK study, including the monitoring of anti-drug antibodies (ADAs). We found that JS-001 specifically bound to PD-1 antigen with an EC50 of 21 nmol/L, and competently blocked the binding of PD-1 antigen to PD-L1 and PD-L2 with IC50 of 3...
March 20, 2017: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/28300730/the-enrichment-of-hbv-immune-escape-mutations-during-nucleoside-nucleotide-analogue-therapy
#4
Menglin Shan, Zhen Shen, Hua Sun, Jianghua Zheng, Min Zhang
BACKGROUND: Drug-resistant HBV mutants frequently arise during nucleos(t)ide analogues (NAs) therapy, while the resistance mutations on polymerase also have consequent changes in the S protein. Besides, the enrichment of immune-escape mutations was negatively correlated with HBsAg clearance under NAs therapy. This study aims to characterize the variability of hepatitis B virus polymerase and surface antigen in patients with virologic breakthrough under nucleos(t)ide analogues therapy...
March 16, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28296013/long-term-outcome-of-inactive-and-active-low-viremic-hbeag-negative-hepatitis-b-virus-infection-benign-course-towards-hbsag-clearance
#5
Filippo Oliveri, Lidia Surace, Daniela Cavallone, Piero Colombatto, Gabriele Ricco, Nicola Salvati, Barbara Coco, Veronica Romagnoli, Riccardo Gattai, Antonio Salvati, Francesco Moriconi, Quan Yuan, Ferruccio Bonino, Maurizia Rossana Brunetto
BACKGROUND/AIM: The difference between the long-term outcome of low-viremic (HBV-DNA≤20,000-IU/mL, LV-AC) and inactive HBsAg carriers (HBV-DNA≤2,000-IU/mL, IC) remains to be defined. We studied prospectively 153 HBeAg-negative HBsAg-carriers with baseline HBV-DNA≤20,000-IU/mL and normal transaminases. METHODS: IC, LV-AC or chronic hepatitis B (CHB) (HBV-DNA persistently ≤2,000-IU/mL, ≤20,000-IU/mL or >20,000-IU/mL, respectively) were diagnosed after 1-year, 3-monthly monitoring...
March 13, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28291736/association-of-vitamin-d-related-genetic-variations-and-treatment-response-to-pegylated-interferon-in-patients-with-chronic-hepatitis-b
#6
Umaporn Limothai, Natthaya Chuaypen, Apichaya Khlaiphuengsin, Salyavit Chittmittraprap, Yong Poovorawan, Pisit Tangkijvanich
BACKGROUND: Vitamin D, a potent immune-modulator, has been linked to the pathogenesis of chronic hepatitis B (CHB). This study was aimed at investigating the association between single nucleotide polymorphisms (SNPs) in vitamin D-related genes and treatment response to pegylated interferon (PEG-IFN) in patients with CHB. METHODS: A total 275 Thai patients (122 HBeAg-positive and 153 HBeAg-negative CHB) treated with 48-week PEG-IFN were recruited. Virological response (VR) at 48 weeks post treatment was defined as HBeAg seroconversion plus HBV DNA <2,000 IU/mL for HBeAg-positive CHB and HBV DNA <2,000 IU/mL for HBeAg-negative CHB...
March 14, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28252163/a-large-scale-analysis-study-on-the-clinical-and-viral-characteristics-of-hepatitis-b-infection-with-concurrence-of-hepatitis-b-surface-or-e-antigens-and-their-corresponding-antibodies
#7
Y Xiang, P Chen, J R Xia, L P Zhang
Concurrent detection of hepatitis B surface antigen (HBsAg) and anti-HBs antibody or hepatitis B surface E antigen (HBeAg) and anti-HBe antibody in patients with chronic hepatitis B (CHB) infection is well established. However, the clinical implications of these proteins remain largely unknown. In this study, demographic, clinical, and laboratory data from 124,865 patients with chronic CHB infection were analyzed. Viral genotypes were determined by nested polymerase chain reaction. A chemiluminescent assay was applied to measure HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb in sera...
February 23, 2017: Genetics and Molecular Research: GMR
https://www.readbyqxmd.com/read/28240596/discontinuation-of-lamivudine-treatment-in-hbeag-negative-chronic-hepatitis-b-a-pilot-study-with-long-term-follow-up
#8
Fatih Karakaya, Sevil Özer, Çağdaş Kalkan, E Ali Tüzün, Aysun Çalışkan, Onur Keskin, Gökhan Kabaçam, Senem Karatayli, Ersin Karatayli, A Mithat Bozdayi, Ramazan Idilman, Cihan Yurdaydin
BACKGROUND: Finite treatment of HBeAg-negative chronic hepatitis B (CHB) with nucleos(t)ide analogs (NAs) is important in resource limited countries. Outcome of treatment discontinuation in patients on long-term lamivudine (LVD) was assessed in a single center observational pilot study in the current study. METHODS: Non-cirrhotic patients on LVD for at least 5 years with undetectable HBV DNA on at least two consecutive assessments were offered to stop treatment...
February 27, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28207518/virological-and-serological-features-of-acute-hepatitis-b-in-adults
#9
Xiaofei Du, Yali Liu, Lina Ma, Junfeng Lu, Yi Jin, Shan Ren, Zhimin He, Xinyue Chen
Various viral kinetics among patients with acute hepatitis B (AHB) have been observed in clinical practice. This study investigated the virological, biochemical, and serological characteristics of AHB in adults.A total of 192 adult patients with AHB were recruited between December 2010 and January 2014. The quantification of biochemical and serologic markers for hepatitis B virus (HBV) infection was monitored from the onset.Of the 192 patients, 113 patients were followed up. One patient died due to acute liver failure, 2 developed chronic HBV infection...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28121714/hepatitis-delta-and-hiv-infection
#10
Vincent Soriano, Kenneth E Sherman, Pablo Barreiro
Viral liver diseases are frequent co-morbidities and major contributors to death in HIV-positive individuals on antiretroviral therapy. Whereas cure of hepatitis C and control of hepatitis B with antivirals avert liver disease progression in most HIV-coinfected patients, the lack of satisfactory treatment for hepatitis delta virus (HDV) infection remains a major threat for developing cirrhosis and liver cancer in this population. In the European Union and North America, sexual contact has replaced injection drug use has major transmission route for HDV in HIV-positive persons...
January 24, 2017: AIDS
https://www.readbyqxmd.com/read/28092214/treatment-of-delta-hepatitis-today-and-in-the-future-a-review
#11
REVIEW
Ibrahim Halil Bahcecioglu, Abdurrahman Sahin
Hepatitis delta virus (HDV) is a defective satellite virus and propagates in the presence of Hepatitis B virus (HBV) surface antigen (HBsAg). Approximately 5% of the people who infected with HBV are also infected with HDV. Chronic hepatitis caused by delta is the most severe form of chronic viral hepatitis including accelerated fibrosis, liver decompensation and development of hepatocellular carcinoma. Interferon-based therapies still remain the only treatment option of the hepatitis delta. The beneficiary effects of the interferon-based therapies, however, stop frequently with termination of the given therapy and relapse rate is very high...
April 2017: Infectious Diseases
https://www.readbyqxmd.com/read/28073409/-a-study-of-immune-response-to-hbsag-mediated-by-cd4-memory-t-lymphocytes-in-immunized-hbv-transgenic-mice
#12
Y Li, J H Chen, X G Shu, J H Chen, Q H Xia, W Z Yuan, L Wu, Q Tang, G B Wang
Objective: To investigate the mechanism of immune response to HBsAg mediated by CD4+ memory T lymphocytes in immunized HBV transgenic (Tg) mice. Methods: Peripheral CD4+ memory T lymphocytes were isolated and collected by magnetic bead sorting from C57BL/6 mice successfully immunized by hepatitis B vaccine. Adoptive immunization was performed for Tg mice by caudal vein injection, and the peripheral blood was collected at 4 and 8 weeks after adoptive immunization. Enzyme-linked immunosorbent assay was used to measure the levels of HBsAg, anti-HBs, interferon-γ (IFNγ), and interleukin-2 (IL-2), and immunohistochemistry was used to measure the level of HBsAg in the liver...
December 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/28056752/inhibiting-the-secretion-of-hepatitis-b-surface-antigen-hbsag-to-treat-hepatitis-b-infection-a-review
#13
Simon D Baugh
Chronic Hepatitis B is a major global health issue, and has no known cure. Currently there are over 240 million people infected with the disease, and it leads to the death of over 686,000 people each year. A total of seven treatments which help to control the disease are currently available: interferon-based treatments (pegasys, and interferon alpha), and nucleoside and nucleotide analogs (Viread, Baraclude, Tyzeka, Hepsera, Epivir-HBV), but all require continuing treatment to maintain control of the disease...
January 4, 2017: Infectious Disorders Drug Targets
https://www.readbyqxmd.com/read/28052637/future-anti-hbv-strategies
#14
REVIEW
Edward J Gane
Although current oral antivirals can maintain viral suppression and reduce the risk of liver-related complications, lifelong therapy is associated with high cost, risk of breakthrough and potential toxicity. There is a need to develop a finite course of treatment which can provide sustained off-treatment virological and clinical response. The likely marker of such a clinical HBV CURE would be HBsAg clearance, but in addition cccDNA elimination would be required to prevent future reactivation (ie complete HBV cure)...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28012213/antibody-dependent-and-independent-uptake-of-hbsag-across-human-leukocyte-subsets-is-similar-between-individuals-with-chronic-hepatitis-b-virus-infection-and-healthy-donors
#15
Hugo Tharinger, Indrani Rebbapragada, Dharmaraj Samuel, Nikolai Novikov, Mindie Nguyen, Robert Jordan, Christian R Frey, Stefan Pflanz
Maintaining detectable levels of antibodies to hepatitis B surface antigen (HBsAg) in serum, i.e. HBsAg sero-conversion, is the key clinical endpoint indicative of recovery from infection with hepatitis B virus (HBV). HBV-infected hepatocytes secrete HBsAg sub-viral particles in vast excess over HBV virions. Therefore, detectable hepatitis B surface antibody (anti-HBs) titers imply complete elimination of HBV virions as well as HBsAg particles. Although intrahepatic phagocytes, e.g. Kupffer cells, are thought to mediate clearance of HBsAg via antibody (Ab)-dependent and -independent mechanisms, the relative contributions of circulating phagocytic cell types to HBsAg elimination are poorly characterized...
December 23, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27998820/core-i97l-mutation-in-conjunction-with-p79q-is-associated-with-persistent-low-hbv-dna-and-hbs-antigen-clearance-in-patients-with-chronic-hepatitis-b
#16
T Honda, M Ishigami, Y Ishizu, T Kuzuya, K Hayashi, T Ishikawa, Y Murakami, M Iwadate, H Umeyama, H Toyoda, T Kumada, Y Katano, H Goto, Y Hirooka
OBJECTIVES: When considering treatment for chronic hepatitis B (CHB), it is important to discriminate between patients with persistent low HBV DNA and patients with active hepatitis, who may proceed to cirrhosis. In this study, we sought to identify mutations in patients expected to have persistent low HBV DNA and ultimately exhibit clearance of hepatitis B surface antigen (HBsAg). METHODS: Serum samples were obtained from 33 CHB genotype C patients, divided based on HBV DNA and alanine aminotransferase (ALT) levels following observation for >2 years: Group A (n=10), transient HBV DNA ≥5...
December 18, 2016: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/27955711/hcv-co-infection-and-markers-of-liver-injury-and-fibrosis-among-hiv-positive-childbearing-women-in-ukraine-results-from-a-cohort-study
#17
Heather Bailey, Nataliya Nizova, Violeta Martsynovska, Alla Volokha, Ruslan Malyuta, Mario Cortina-Borja, Claire Thorne
BACKGROUND: Ukraine's injecting drug use-driven HIV epidemic is among the most severe in Europe with high burden of HCV co-infection. HIV/HCV co-infected individuals are at elevated risk of HCV-related morbidity, but little is known about burden of liver disease and associated factors in the HIV-positive population in Ukraine, particularly among women. METHODS: Characteristics of 2050 HIV-positive women enrolled into the Ukrainian Study of HIV-infected Childbearing Women were described by HCV serostatus...
December 12, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27938558/-a-retrospective-study-on-hbsag-clearance-rate-after-antiviral-therapy-in-children-with-hbeag-positive-chronic-hepatitis-b-aged-1-7-years
#18
S S Zhu, Y Dong, Z Q Xu, L M Wang, D W Chen, Y Gan, F C Wang, J G Yan, L L Cao, P Wang, H F Zhang
Objective: To investigate the HBsAg clearance rate after antiviral therapy in children with HBeAg-positive chronic hepatitis B (CHB) aged 1-7 years. Methods: A retrospective analysis was performed for the HBsAg clearance rate in 293 children who were hospitalized in 302 Hospital of PLA from June 2006 to December 2013, met the inclusion criteria, received antiviral therapy, and were followed up for at least 6 months after the withdrawal of antiviral therapy. The t-test or the rank sum test was applied according to the distribution of continuous data, and the chi-square test was used for comparison of categorical data...
October 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/27935953/factors-predicting-hbsag-seroclearance-and-alanine-transaminase-elevation-in-hbeag-negative-hepatitis-b-virus-infected-patients-with-persistently-normal-liver-function
#19
Tai-Long Chien, Jing-Houng Wang, Kwong-Ming Kee, Chien-Hung Chen, Chao-Hung Hung, Sheng-Nan Lu
BACKGROUND: A certain proportion of hepatitis B virus (HBV)-infected patients with persistently normal alanine transaminase (ALT) levels have significant fibrosis. Using liver stiffness measurements (Fibroscan®) and laboratory data, including serum ALT, quantitative HBsAg (qHBsAg), and HBV DNA, we attempted to predict the natural histories of these patients. METHODS: Non-cirrhotic HBeAg-negative chronic hepatitis B patients with persistently normal ALT were followed up prospectively with the end points of HBsAg seroclearance and ALT elevation above the upper limit of normal...
2016: PloS One
https://www.readbyqxmd.com/read/27827798/unimpaired-immunogenicity-of-yeast-expressed-hepatitis-b-surface-antigen-stored-at-elevated-temperatures
#20
Zhongliang Shen, Yuliang Rao, Shuai Tao, Mengjun Luo, Lijun Ming, Jing Liu, Shaokun Pan, Youhua Xie
Global adoption of hepatitis B virus (HBV) vaccines has greatly reduced new HBV infections. Current HBV vaccines are liquid suspensions containing recombinant hepatitis B surface antigen (HBsAg) particles mixed with aluminum phosphate or aluminum hydroxide. Refrigeration (2-8°C) as recommended for vaccine transport and storage may be unachievable in certain HBV-prevalent developing countries or regions. In this study, we stored yeast-expressed HBsAg and aluminum hydroxide separately at the standard (4°C) and elevated temperature (25, 37, or 45°C) for 14, 23, and 30 days, then mixed them and used the mixture to vaccinate mice with a prime-boost program...
December 2016: Acta Biochimica et Biophysica Sinica
keyword
keyword
42773
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"